What is new in your approach to treating peritoneal mesothelioma?

The management of peritoneal carcinomatosis at the Washington Cancer Institute combines intraoperative, early postoperative, and bidirectional long-term chemotherapy. In the operating room HIPEC is used. Then, if the patient's condition is stable, moderate dose intraperitoneal paclitaxel is used for 5 days. In most patients we place an intraperitoneal port. Over the course of the next six months combined intraperitoneal pemetrexed (Alimta) and systemic cisplatin are administered as tolerated by the patient. With this combined approach local-regional control has been excellent.

--Paul H. Sugarbaker, MD, FACS, FRCS, Washington Hospital Center


What do you hope to achieve as the new SAB Chair?

Why is clinical trial participation important in mesothelioma?

How does a pathologist diagnose mesothelioma?

Why is a second opinion important in mesothelioma?

My doctor told me that chemotherapy doesn’t work in mesothelioma. Is this true?

What advances have you seen over the years in gene therapy for mesothelioma?

What is new in your approach to treating peritoneal mesothelioma?

Is radiation therapy effective for pain control for patients with mesothelioma?

Can you tell me about the potential benefit of IMRT in mesothelioma?


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376